Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP273401.RAh_B3fm_qdeDRqL81Ld56WFTiBbNOx37ACH_c6ezuX1g130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP273401.RAh_B3fm_qdeDRqL81Ld56WFTiBbNOx37ACH_c6ezuX1g130_assertion type Assertion NP273401.RAh_B3fm_qdeDRqL81Ld56WFTiBbNOx37ACH_c6ezuX1g130_head.
- NP273401.RAh_B3fm_qdeDRqL81Ld56WFTiBbNOx37ACH_c6ezuX1g130_assertion description "[A phase II study of the PARP inhibitor olaparib (AstraZeneca) for cancer patients with inherited BRCA1 and BRCA2 gene mutations confirmed earlier results showing clinical benefit for advanced breast and ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP273401.RAh_B3fm_qdeDRqL81Ld56WFTiBbNOx37ACH_c6ezuX1g130_provenance.
- NP273401.RAh_B3fm_qdeDRqL81Ld56WFTiBbNOx37ACH_c6ezuX1g130_assertion evidence source_evidence_literature NP273401.RAh_B3fm_qdeDRqL81Ld56WFTiBbNOx37ACH_c6ezuX1g130_provenance.
- NP273401.RAh_B3fm_qdeDRqL81Ld56WFTiBbNOx37ACH_c6ezuX1g130_assertion SIO_000772 23847380 NP273401.RAh_B3fm_qdeDRqL81Ld56WFTiBbNOx37ACH_c6ezuX1g130_provenance.
- NP273401.RAh_B3fm_qdeDRqL81Ld56WFTiBbNOx37ACH_c6ezuX1g130_assertion wasDerivedFrom befree-20150227 NP273401.RAh_B3fm_qdeDRqL81Ld56WFTiBbNOx37ACH_c6ezuX1g130_provenance.
- NP273401.RAh_B3fm_qdeDRqL81Ld56WFTiBbNOx37ACH_c6ezuX1g130_assertion wasGeneratedBy ECO_0000203 NP273401.RAh_B3fm_qdeDRqL81Ld56WFTiBbNOx37ACH_c6ezuX1g130_provenance.